• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
FIGURE 104. Random-effects meta-analysis – CDR at 12 weeks (mean change from baseline): donepezil (5 mg/day) vs placebo.

FIGURE 104Random-effects meta-analysis – CDR at 12 weeks (mean change from baseline): donepezil (5 mg/day) vs placebo

From: Appendix 5, Combined-dose and dose-specific meta-analyses

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.